Choice of active comparator for fingolimod
| Disease-modifying therapy | Indication | Approved treatment order | Route of administration | Approval year in Canada |
| Fingolimod | RRMS | 2 | Oral | 2011 |
| Natalizumab | RRMS | 2 | Intravenous | 2006 |
| Alemtuzumab | RRMS | 2 | Intravenous | 2013 |
| Dimethyl fumarate | RRMS | 1 | Oral | 2013 |
| Teriflunomide | RRMS | 1 | Oral | 2013 |
| Cladribine | RRMS | 2 | Oral | 2017 |
| Glatiramer acetate | RRMS | 1 | Subcutaneous injection | 1997 |
| Interferon β | RRMS | 1 | Subcutaneous injection | 1995 |
| Rituximab | Off-label for RRMS | N/A | Intravenous | N/A |
| Ocrelizumab | RRMS; PPMS | 1 | Intravenous | 2017 |
Green represents consistency with fingolimod properties, red represents inconsistency.
PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis.